National Healthcare Agreement: PB c–Better health: reduce the age-adjusted prevalence rate for Type 2 diabetes to 2000 levels (equivalent to a national prevalence rate (for 25 years and over) of 7.1 per cent) by 2023, 2021
Identifying and definitional attributes
|Metadata item type:||Indicator|
|Short name:||PB c–Reduce the age-adjusted prevalence rate for Type 2 diabetes to 2000 levels (equivalent to a national prevalence rate (for 25 years and over) of 7.1 per cent) by 2023, 2021|
|Registration status:||Health, Standard 03/07/2020|
Proportion of people with Type 2 diabetes.
|Indicator set:||National Healthcare Agreement (2021) Health, Standardisation pending 03/08/2020|
|Outcome area:||Prevention Health, Standard 07/07/2010|
Collection and usage attributes
The National Health Measures Survey component of the 2011–13 Australian Health Survey (ABS cat. no. 4364.0.55.005) included a fasting plasma glucose test.
A respondent to the survey is considered to have known diabetes if they had ever been told by a doctor or nurse that they have Type 2 diabetes and:
A respondent to the survey is considered to have newly diagnosed diabetes if they reported no prior diagnosis of diabetes, but had a fasting plasma glucose value greater than or equal to 7.0 mmol/L.
Excludes persons who did not fast for 8 hours or more prior to their blood test.
Excludes women with gestational diabetes.
Population is limited to persons aged 25 and over.
Rates are directly age-standardised to the 2001 Australian population.
Analysis by remoteness and Socio-Economic Indexes for Areas (SEIFA) Index of Relative Socio-Economic Disadvantage (IRSD) is based on usual residence of person (subject to data availability).
Presented as a percentage.
95% confidence intervals and relative standard errors calculated for rates.
Note: The type of diabetes for newly diagnosed cases cannot be determined from a fasting plasma glucose test alone. However, it is assumed that the vast majority of newly diagnosed cases would be Type 2.
100 x (numerator/denominator)
Number of persons aged 25 and over with known diabetes (Type 2) or newly diagnosed diabetes as determined by a fasting plasma glucose test.
|Numerator data elements:|
Population aged 25 and over.
|Denominator data elements:|
State and territory, by:
State and territory by Indigenous status (Indigenous only).
Some disaggregations may result in numbers too small for publication.
|Disaggregation data elements:|
Most recent data available for 2021 National Healthcare Agreement performance reporting: 2011–12 (total population, non-Indigenous: AHS); 2012–13 (Indigenous only: AATSIHS).
NO NEW DATA FOR 2021 REPORTING.
The baseline measure of 7.1% is calculated from the Australian Diabetes, Obesity and Lifestyle Study conducted in 1999–2000. Note that this number was age-standardised to the average of the 1999 and 2000 Australian populations, and was based on data from both oral glucose tolerance tests (OGTTs) and fasting plasma glucose tests. As an OGTT was not conducted as part of the National Health Measures Survey, the data supplied for the 2014 COAG Reform Council report are not comparable to the baseline measure of 7.1%.
Fasting plasma glucose test data will be supplied as a proxy from the AHS for this benchmark, age-standardised to the 2001 Australian population. The equivalent baseline measure from the Australian Diabetes, Obesity and Lifestyle Study, age-standardised to the 2001 Australian population and using fasting plasma glucose test data, has been calculated to be a rate of 5.0%.
|Unit of measure:||Person|
Indicator conceptual framework
|Framework and dimensions:||Health conditions|
Data source attributes
National Healthcare Agreement
|Organisation responsible for providing data:|
Australian Bureau of Statistics
National Healthcare Agreement Performance Benchmark:
Reduce the age-adjusted prevalence rate for Type 2 diabetes to 2000 levels (equivalent to a national prevalence rate (for 25 years and over) of 7.1%) by 2023.
|Further data development / collection required:|
Specification: Final, the measure meets the intention of the indicator.
Source and reference attributes
Australian Bureau of Statistics (ABS) 2013. Australian Health Survey: Biomedical Results for Chronic Diseases, 2011–12, ABS cat. no. 4364.0.55.005. Canberra: ABS. Viewed 11 May 2020, https://www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/
Baker Heart & Diabetes Institute n.d. About AusDiab. Melbourne: Baker Heart & Diabetes Institute. Viewed 11 May 2020, https://www.baker.edu.au/ausdiab/
Council of Australian Governments 2012. National Healthcare Agreement (effective 25 July 2012). Viewed 5 May 2020, http://www.federalfinancialrelations.gov.au/content/npa/health/
|Related metadata references:|
Supersedes National Healthcare Agreement: PB c–Better health: reduce the age-adjusted prevalence rate for Type 2 diabetes to 2000 levels (equivalent to a national prevalence rate (for 25 years and over) of 7.1 per cent) by 2023, 2020 Health, Standard 13/03/2020
See also National Healthcare Agreement: PI 10–Prevalence of Type 2 diabetes, 2021 Health, Standard 03/07/2020
See also National Healthcare Agreement: PI 15–Effective management of diabetes, 2021 Health, Standard 03/07/2020